港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,793.042

+20.8101.17%

漲家數：4

跌家數：4

平家數：- -

市盈率：- -

高：1,835.570

開：1,770.415

低：1,747.549

收：1,772.232

資料載入中...

昆藥集團(600422.SH)：天麻素注射液臨牀試驗獲批准

泰格醫藥02月28日遭主力拋售483萬元

昭衍新藥02月28日遭主力拋售492萬元

維亞生物(01873)股價下跌9.091%，現價港幣$1.3

阿斯达克财经

泰格醫藥盤中異動下午盤急速跳水5.09%報34.500港元

維亞生物盤中異動下午盤快速跳水5.59%

金斯瑞生物科技盤中異動下午盤快速跳水5.13%

藥明生物(02269)下跌5.07%，報22.45元/股

藥明生物盤中異動股價大跌5.07%

康龍化成盤中異動股價大跌5.11%報15.980港元

昭衍新藥盤中異動早盤快速跳水5.40%

藥明康德盤中異動早盤大幅下跌3.03%報60.800港元

復星醫藥(02196.HK)子公司獲藥品臨牀試驗批准

阿斯达克财经

復星醫藥(02196)：星盛新輝收到國家藥監局關於同意XS-03片的藥品臨牀試驗批准

【眾生藥業：控股子公司獲得一類創新藥RAY1225注射液III期臨牀試驗倫理批件】金融界2月27日消息，近日，眾生藥業控股子公司眾生睿創自主研發的一類創新多肽藥物RAY1225注射液在超重/肥胖參與者的安全性和有效性的多中心、隨機、雙盲、安慰劑對照的III期臨牀試驗獲得組長單位北京大學人民醫院和共同組長單位中山大學孫逸仙紀念醫院倫理審查批件，批准項目開展。RAY1225注射液是具有全球自主知識產權的創新結構多肽藥物，屬於長效GLP-1類藥物，具有雙重激動活性，可調節人體代謝和控制血糖。本次III期臨牀試驗組長單位倫理批件的獲得，標誌着該試驗將全面啓動。該注射液獲得倫理批件對公司短期財務狀況和經營業績不構成重大影響，但臨牀試驗存在風險和不確定性，公司將按規定履行信息披露義務。

【眾生藥業：RAY1225注射液III期臨牀試驗倫理批件獲批】眾生藥業公告，控股子公司眾生睿創自主研發的RAY1225注射液在超重/肥胖參與者的安全性和有效性的多中心、隨機、雙盲、安慰劑對照的III期臨牀試驗(REBUILDING-2)獲得組長單位北京大學人民醫院和共同組長單位中山大學孫逸仙紀念醫院倫理審查批件，批准項目開展。RAY1225注射液是眾生睿創研發的、具有全球自主知識產權的創新結構多肽藥物，屬於長效GLP-1類藥物，具有GLP-1受體和GIP受體雙重激動活性，可通過刺激胰島素分泌、延緩胃排空等機制調節人體代謝和控制血糖，有望用於降糖、減肥、代謝綜合徵等多種代謝性疾病的治療。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1793.0419,"timestamp":1741334919514,"preClose":1772.232,"halted":0,"volume":105965997,"delay":0,"changeRate":0.011742,"change":20.809814,"pbRate":2.65369,"amount":2334342230,"amplitude":0.049667,"prevYearClose":1395.7731,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"turnoverRate":0.008873,"marketCap":381645564416,"floatMarketCap":165840598400,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1835.5696,"amplitude":0.049667,"preClose":1772.232,"low":1747.5487,"pbRate":"2.65369","latestPrice":1793.0419,"volume":105965997,"delay":0,"open":1770.415,"prevYearClose":1395.7731,"prevWeekClose":1793.042,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"sixtyDayClose":1337.64,"secType":"PLATE","market":"HK","turnoverRate":0.008873,"peRate":33.079805,"marketCap":381645564416,"floatMarketCap":165840598400,"timestamp":1741334919514,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":4,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514435243","title":"昆藥集團(600422.SH)：天麻素注射液臨牀試驗獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514435243","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514435243?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 17:15","pubTimestamp":1740734140,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昆药集团(600422.SH)公告，公司近日收到国家药品监督管理局签发的天麻素注射液按照化学药品2.4类新药受理的《药物临床试验批准通知书》，同意该新药开展相关临床试验研究，该新药适应症为：预防心脏外科术后谵妄。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","600422","BK1576","BK1583","BK0239","03347","BK0188","BK0028","BK0060"],"gpt_icon":0},{"id":"2514348825","title":"泰格醫藥02月28日遭主力拋售483萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514348825","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514348825?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 16:17","pubTimestamp":1740730640,"startTime":"0","endTime":"0","summary":"02月28日, 泰格医药股价跌6.88%，报收33.85元，成交金额1.78亿元，换手率4.16%，振幅9.90%，量比0.71。泰格医药今日主力资金净流出483万元，上一交易日主力净流出37万元。该股近5个交易日下跌13.08%，主力资金累计净流出2704万元；近20日主力资金累计净流入1251万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165711a2579d8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165711a2579d8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","03347","BK1583"],"gpt_icon":0},{"id":"2514348385","title":"昭衍新藥02月28日遭主力拋售492萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514348385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514348385?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 16:16","pubTimestamp":1740730597,"startTime":"0","endTime":"0","summary":"02月28日, 昭衍新药股价跌15.04%，报收13.22元，成交金额8936万元，换手率5.41%，振幅17.74%，量比0.86。昭衍新药今日主力资金净流出492万元，上一交易日主力净流出145万元。该股近5个交易日下跌2.81%，主力资金累计净流出88万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入2110万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165606a2579d0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165606a2579d0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","BK1576","BK1141"],"gpt_icon":0},{"id":"2514397299","title":"維亞生物(01873)股價下跌9.091%，現價港幣$1.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2514397299","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514397299?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 14:25","pubTimestamp":1740723900,"startTime":"0","endTime":"0","summary":"[下跌股]维亚生物(01873) 股价在下午02:25比前收市价下跌9.091%，现股价为港币$1.3。至目前为止，今日最高价为$1.43，而最低价为$1.3。总成交量为320.2万股，总成交金额为港币$438.336万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2502286799/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","BK1576","01873"],"gpt_icon":0},{"id":"2514391159","title":"泰格醫藥盤中異動 下午盤急速跳水5.09%報34.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514391159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514391159?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 13:38","pubTimestamp":1740721101,"startTime":"0","endTime":"0","summary":"2025年02月28日下午盘13时38分，泰格医药股票出现波动，股价快速跳水5.09%。截至发稿，该股报34.500港元/股，成交量251.09万股，换手率2.04%，振幅6.74%。资金方面，该股资金流入3535.17万港元，流出4007.46万港元。最近的财报数据显示，该股实现营业收入56.20亿港元，净利润9.02亿港元，每股收益1.04港元，毛利21.85亿港元，市盈率13.34倍。泰格医药股票所在的生物技术行业中，整体跌幅为0.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281338219895dcd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281338219895dcd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","BK1583","03347"],"gpt_icon":0},{"id":"2514539417","title":"維亞生物盤中異動 下午盤快速跳水5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514539417","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514539417?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 13:20","pubTimestamp":1740720002,"startTime":"0","endTime":"0","summary":"2025年02月28日下午盘13时20分，维亚生物股票出现波动，股价快速下跌5.59%。截至发稿，该股报1.350港元/股，成交量247.45万股，换手率0.12%，振幅5.59%。资金方面，该股资金流入135.189万港元，流出194.393万港元。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。维亚生物股票所在的生物技术行业中，整体跌幅为0.05%。维亚生物公司简介：维亚生物科技控股集团是一家投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228132002a2575429&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228132002a2575429&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","01873","BK1141"],"gpt_icon":0},{"id":"2514399941","title":"金斯瑞生物科技盤中異動 下午盤快速跳水5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514399941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514399941?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 13:11","pubTimestamp":1740719483,"startTime":"0","endTime":"0","summary":"2025年02月28日下午盘13时11分，金斯瑞生物科技股票出现波动，股价急速跳水5.13%。截至发稿，该股报12.580港元/股，成交量1180.31万股，换手率0.55%，振幅5.73%。金斯瑞生物科技股票所在的生物技术行业中，整体涨幅为0.10%。金斯瑞生物科技公司简介：金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228131123abe03ff3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228131123abe03ff3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","HK0000320223.HKD","HK0000306685.HKD","01548","HK0000320264.USD","BK1583","HK0000306701.USD"],"gpt_icon":0},{"id":"2514360108","title":"藥明生物(02269)下跌5.07%，報22.45元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2514360108","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514360108?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 11:20","pubTimestamp":1740712824,"startTime":"0","endTime":"0","summary":"2月28日，药明生物(02269)盘中下跌5.07%，截至11:20，报22.45元/股，成交6.66亿元。药明生物技术有限公司是全球领先的生物制剂服务供应商，提供全面、综合及高度定制的服务，包括从发现、开发到生产生物制剂的全过程。公司在2016年在中国生物制剂研发市场占有48%的市场份额，已与全球20大制药公司中的12家建立合作关系。截至2024年中报，药明生物营业总收入85.74亿元、净利润14.99亿元。3月25日，药明生物将披露2024财年年报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/28112048448598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0052750758.USD","LU0708995583.HKD","LU0307460666.USD","LU0516422366.SGD","LU0417516902.SGD","SG9999002562.SGD","LU0516423174.USD","IE00B0JY6N72.USD","LU0181495838.USD","LU0039217434.USD","LU0516422440.USD","LU0856984785.SGD","LU1720050803.USD","BK1589","BK1576","LU0417516738.SGD","LU0979878070.USD","LU0819121731.USD","LU0823426308.USD","BK1610","LU1242518931.SGD","LU0348735423.USD","LU0326950275.SGD","BK1141","LU0588546209.SGD","BK1521","LU0043850808.USD","LU0140636845.USD","LU0327786744.USD","LU0348825331.USD","LU0320764599.SGD","LU0456827905.SGD","LU1242518857.USD","LU1880383366.USD","LU0359202008.SGD","SG9999002463.SGD","LU1794554557.SGD","LU0516423091.SGD","LU0051755006.USD","02269","LU0359201612.USD","LU0456846285.SGD","LU0516422952.EUR","LU0572944931.SGD","LU0823426480.USD","LU2039709279.SGD","LU1688375341.USD"],"gpt_icon":0},{"id":"2514589360","title":"藥明生物盤中異動 股價大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514589360","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514589360?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 11:20","pubTimestamp":1740712822,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘11时20分，药明生物股票出现波动，股价快速跳水5.07%。截至发稿，该股报22.450港元/股，成交量2900.51万股，换手率0.71%，振幅5.07%。资金方面，该股资金流入2.45638亿港元，流出3.71824亿港元。药明生物股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，迈博药业-B、帝王国际投资、奥星生命科技涨幅较大，振幅较大的相关个股有帝王国际投资、科笛-B、昭衍新药，振幅分别为23.08%、16.33%、13.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281120229895bbd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502281120229895bbd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516902.SGD","LU1720050803.USD","LU0417516738.SGD","LU0572944931.SGD","LU0327786744.USD","LU0051755006.USD","02269","LU0052750758.USD","LU0823426480.USD","IE00B0JY6N72.USD","LU0140636845.USD","LU0348735423.USD","LU0516423174.USD","LU1688375341.USD","SG9999002562.SGD","BK1610","LU1242518931.SGD","SG9999002463.SGD","LU0823426308.USD","LU0708995583.HKD","LU1242518857.USD","BK1576","LU0348825331.USD","LU0359202008.SGD","LU0307460666.USD","LU0516422440.USD","LU0856984785.SGD","LU0039217434.USD","LU1880383366.USD","LU0326950275.SGD","LU0516422366.SGD","LU0359201612.USD","LU0043850808.USD","LU0516422952.EUR","BK1141","LU1794554557.SGD","LU0819121731.USD","LU0181495838.USD","LU0516423091.SGD","LU0588546209.SGD","LU0320764599.SGD","LU2039709279.SGD","BK1589","LU0456846285.SGD","LU0456827905.SGD","LU0979878070.USD","BK1521"],"gpt_icon":1},{"id":"2514364584","title":"康龍化成盤中異動 股價大跌5.11%報15.980港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514364584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514364584?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 10:17","pubTimestamp":1740709026,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘10时17分，康龙化成股票出现异动，股价急速跳水5.11%。截至发稿，该股报15.980港元/股，成交量318.08万股，换手率1.08%，振幅4.99%。资金方面，该股资金流入1074.81万港元，流出3151.3万港元。康龙化成股票所在的药品行业中，整体跌幅为0.65%。其相关个股中，君圣泰医药-B、海王英特龙、草姬集团涨幅较大，振幅较大的相关个股有德琪医药-B、开拓药业-B、艾美疫苗，振幅分别为17.48%、11.67%、7.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022810170796334b74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022810170796334b74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","03759"],"gpt_icon":0},{"id":"2514836696","title":"昭衍新藥盤中異動 早盤快速跳水5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514836696","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514836696?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 09:38","pubTimestamp":1740706715,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘09时38分，昭衍新药股票出现异动，股价快速跳水5.40%。截至发稿，该股报14.720港元/股，成交量25.34万股，换手率0.21%，振幅7.58%。昭衍新药股票所在的生物技术行业中，整体涨幅为1.61%。其相关个股中，百济神州、永泰生物-B、华昊中天医药-B涨幅较大，振幅较大的相关个股有科笛-B、永泰生物-B、创胜集团-B，振幅分别为11.71%、10.40%、8.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228093835abe00558&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228093835abe00558&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","06127"],"gpt_icon":0},{"id":"2514636662","title":"藥明康德盤中異動 早盤大幅下跌3.03%報60.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514636662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514636662?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 09:37","pubTimestamp":1740706637,"startTime":"0","endTime":"0","summary":"2025年02月28日早盘09时37分，药明康德股票出现波动，股价急速跳水3.03%。截至发稿，该股报60.800港元/股，成交量49.1656万股，换手率0.13%，振幅2.63%。资金方面，该股资金流入769.087万港元，流出1732.96万港元。药明康德股票所在的生物技术行业中，整体涨幅为1.61%。其相关个股中，百济神州、永泰生物-B、华昊中天医药-B涨幅较大，振幅较大的相关个股有科笛-B、永泰生物-B、创胜集团-B，振幅分别为11.71%、10.40%、8.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022809371798959ab7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022809371798959ab7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2242644610.SGD","LU2125910500.SGD","LU2045819591.USD","LU1046422090.SGD","LU0320764599.SGD","BK1576","02359","BK1141","LU0052750758.USD","BK1583","LU0708995583.HKD"],"gpt_icon":0},{"id":"2514891423","title":"復星醫藥(02196.HK)子公司獲藥品臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514891423","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514891423?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 23:16","pubTimestamp":1740669360,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司星盛新辉收到国家药品监督管理局关于同意 XS-03片与FOLFOX 或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌临床试验的批准。该治疗方案中所涉XS-03为集团自主研发的小分子口服PLK1 抑制剂。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-27 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420857/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0012","BK0188","BK0239","BK1593","BK0196","03347","BK1583","BK0187","BK0028","BK1141","02196","BK0096","BK0175","BK0060","BK0183","600196","BK1515","BK1191","BK1576"],"gpt_icon":0},{"id":"2514492874","title":"復星醫藥(02196)：星盛新輝收到國家藥監局關於同意XS-03片的藥品臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514492874","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514492874?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 18:42","pubTimestamp":1740652968,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，该公司控股子公司江苏星盛新辉医药有限公司于近日收到国家药品监督管理局关于同意XS-03片与FOLFOX或FOLFIRI 和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌临床试验的批准。截至目前的研究显示，XS-03 在多种肿瘤模型中展现较为显著的抑制肿瘤生长的药效，且临床安全性良好。截至本公告日期，XS-03 单药用于治疗RAS突变晚期实体瘤于中国境内处于I期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","03347","BK1191","BK1515","BK0060","BK0175","BK0239","BK1593","BK0012","02196","BK0196","BK0096","BK1141","BK1583","BK0028","BK0183","BK1576","BK0187","600196"],"gpt_icon":0},{"id":"2514798938","title":"【眾生藥業：控股子公司獲得一類創新藥RAY1225注射液III期臨牀試驗倫理批件】金融界2月27日消息，近日，眾生藥業控股子公司眾生睿創自主研發的一類創新多肽藥物RAY1225注射液在超重/肥胖參與者的安全性和有效性的多中心、隨機、雙盲、安慰劑對照的III期臨牀試驗獲得組長單位北京大學人民醫院和共同組長單位中山大學孫逸仙紀念醫院倫理審查批件，批准項目開展。RAY1225注射液是具有全球自主知識產權的創新結構多肽藥物，屬於長效GLP-1類藥物，具有雙重激動活性，可調節人體代謝和控制血糖。本次III期臨牀試驗組長單位倫理批件的獲得，標誌着該試驗將全面啓動。該注射液獲得倫理批件對公司短期財務狀況和經營業績不構成重大影響，但臨牀試驗存在風險和不確定性，公司將按規定履行信息披露義務。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514798938","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514798938?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:56","pubTimestamp":1740650165,"startTime":"0","endTime":"0","summary":"金融界2月27日消息，近日，众生药业控股子公司众生睿创自主研发的一类创新多肽药物RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。本次III期临床试验组长单位伦理批件的获得，标志着该试验将全面启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27175648431102.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1141","BK4134","BK4144","03347","BK1583","BK1161","BK1576","GLP","III","BK4590","BK0188","BK0239","159992","BK0077","06978","002317"],"gpt_icon":0},{"id":"2514879859","title":"【眾生藥業：RAY1225注射液III期臨牀試驗倫理批件獲批】眾生藥業公告，控股子公司眾生睿創自主研發的RAY1225注射液在超重/肥胖參與者的安全性和有效性的多中心、隨機、雙盲、安慰劑對照的III期臨牀試驗(REBUILDING-2)獲得組長單位北京大學人民醫院和共同組長單位中山大學孫逸仙紀念醫院倫理審查批件，批准項目開展。RAY1225注射液是眾生睿創研發的、具有全球自主知識產權的創新結構多肽藥物，屬於長效GLP-1類藥物，具有GLP-1受體和GIP受體雙重激動活性，可通過刺激胰島素分泌、延緩胃排空等機制調節人體代謝和控制血糖，有望用於降糖、減肥、代謝綜合徵等多種代謝性疾病的治療。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514879859","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514879859?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 17:55","pubTimestamp":1740650130,"startTime":"0","endTime":"0","summary":"众生药业公告，控股子公司众生睿创自主研发的RAY1225注射液在超重/肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验(REBUILDING-2)获得组长单位北京大学人民医院和共同组长单位中山大学孙逸仙纪念医院伦理审查批件，批准项目开展。RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，属于长效GLP-1类药物，具有GLP-1受体和GIP受体双重激动活性，可通过刺激胰岛素分泌、延缓胃排空等机制调节人体代谢和控制血糖，有望用于降糖、减肥、代谢综合征等多种代谢性疾病的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27175548431160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK1141","GLP","BK0239","III","BK4134","BK1576","002317","BK0077","03347","BK4144","BK4590","BK1583"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":8,"totalSize":218}]}}